Molecular surveillance of anti-malarial resistance Pfdhfr and Pfdhps polymorphisms in African and Southeast Asia Plasmodium falciparum imported parasites to Wuhan, China

Tingting Jiang1,2†, Weijia Cheng1,2†, Yi Yao1,2, Huabing Tan1,2, Kai Wu3* and Jian Li1,2*

Abstract

Background: Anti-malarial drug resistance is a severe challenge for eventual control and global elimination of malaria. Resistance to sulfadoxine-pyrimethamine (SP) increases as mutations accumulate in the Pfdhfr and Pfdhps genes. This study aimed to assess the polymorphisms and prevalence of mutation in these genes in the Plasmodium falciparum infecting migrant workers returning to Wuhan, China.

Methods: Blood samples were collected for 9 years (2011–2019). Parasite genomic DNA was extracted from blood spots on filter paper. The mutations were evaluated by nested PCR and sequencing. The single-nucleotide polymorphisms (SNPs) and haplotypes of the Pfdhfr and Pfdhps genes were analysed.

Results: Pfdhfr codon 108 showed a 94.7% mutation rate, while for Pfdhps, the rate for codon 437 was 79.0%. In total, five unique haplotypes at the Pfdhfr locus and 11 haplotypes at the Pfdhps locus were found while the Pfdhfr-Pfdhps combined locus revealed 28 unique haplotypes. A triple mutant (IRN) of Pfdhfr was the most prevalent haplotype (84.4%). For Pfdhps, a single mutant (SGKAA) and a double mutant (SGEAA) were detected at frequencies of 37.8 and 22.3%, respectively. Among the combined haplotypes, a quadruple mutant (IRN-SGKAA) was the most common, with a 30.0% frequency, followed by a quintuplet mutant (IRN-SGEAA) with a frequency of 20.4%.

Conclusion: The high prevalence and saturation of Pfdhfr haplotypes and the medium prevalence of Pfdhps haplotypes demonstrated in the present data will provide support for predicting the status and progression of antifolate resistance in malaria-endemic regions and imported malaria in nonendemic areas. Additional interventions to evaluate and prevent SP resistance should be continuously considered.

Keywords: Plasmodium falciparum, Sulfadoxine/pyrimethamine, Antimalarial drug resistance, Dihydrofolate reductase, Dihydropteroate synthase, Mutation

Background

Malaria is caused by the Plasmodium parasite, which is transmitted to human beings via the bites of infected female Anopheles mosquitoes. It is prevalent in the tropics and subtropics, particularly sub-Saharan Africa, as well as in Southeast Asia (SEA) and South America. In 2018, there were an estimated 228 million new cases of malaria, which was responsible for approximately
405,000 deaths [1]. Among them, pregnant women and children under 5 years old in Africa are thought to be the primary victims.

In the 1980s, sulfadoxine-pyrimethamine (SP) replaced chloroquine (CQ) as the front-line anti-malaria treatment when large-scale CQ resistance developed in sub-Saharan African countries. However, SP soon had to be replaced by artemisinin-based combination therapy (ACT) due to drug resistance. However, SP is still used for intermittent preventive treatment in infants (IPTi) and pregnant women (IPTp) during malaria-endemic regions, following the guidance of the World Health Organization (WHO) [2]. Furthermore, the administration of SP plus amodiaquine is applied for seasonal malaria chemoprevention (SMC) [3]. Currently, the emergence, development, and continuous dissemination of *Plasmodium falciparum* resistance to the anti-malarial drug is considered a significant global threat for malaria control and elimination strategies [4]. The development of drug resistance could be influenced by multiple factors, including mutation frequency, treatment costs, drug selection pressure, patient compliance, and host immunity [5, 6]. It is necessary to conduct molecular epidemiological surveillance and monitoring of drug-resistant *P. falciparum* parasites from disease-endemic to nonendemic areas. Molecular markers are a useful tool for confirming that parasites are drug-resistant.

For *Plasmodium* spp., enzymes involved in folate metabolism are interfered with by the antifolate anti-malarial drugs. Pyrimethamine acts as an inhibitor in *P. falciparum* dihydrofolate reductase (*Pfdhfr*) and sulfadoxine, targets the *P. falciparum* enzyme dihydropteroylate synthase (*Pfdhps*) [7]. In vitro and in vivo studies have demonstrated resistance to SP is mainly mediated by mutations at codons *Pfdhfr* N51I, C59R, S108N, and I164L, and *Pfdhps* S436A, A437G, K540E, A581G, and A613S [8, 9]. SP resistance, with is very common, is accompanied by the accumulation of these mutations [10–12]. In particular, combinations of multiple mutations in both genes, such as the quadruple mutant carrying four partially resistant mutation in combination, are mainly comprised of the *Pfdhfr* triple mutant (N51I/C59R/S108N) and *Pfdhps* (A437G) [13]. The quintuple mutant genotype includes the *Pfdhfr* (N51I/C59R/S108N) and *Pfdhps* (A437G/K540E). The sextuple mutant consists of a triple mutant (N51I/C59R/S108N) in *Pfdhfr* and a triple mutant (A437G/K540E/A581G) in *Pfdhps*, a combination that was called super resistant [13–15]. Multiple combinations of mutations can affect IPTi and IPTp treatment outcomes. Therefore, it is necessary not only to monitor the increase of mutations at a single site, but also to prevent the potential combination of more other multiple mutations.

This study investigated the prevalence of the mutant and wild-type alleles isolated from *P. falciparum* infecting migrant workers who have returned to Wuhan, central China, who all came from perennial transmission regions from 2011–2019. Such molecular surveillance will provide health authorities with valuable information for adopting efficient anti-malarial drugs in malaria-endemic regions in Africa and malaria nonendemic areas with imported malaria in China particularly Wuhan.

**Methods**

**Samples collection**

Blood samples were collected from *P. falciparum*-infected migrant patients with uncomplicated malaria in Wuhan of Hubei Province from 2011 to 2019. These samples were examined by microscopy with stained thick and thin blood smears and detected by rapid diagnostic tests (RDTs) for Pf-HRP2 and pLDH, as previously described [16–18]. RDTs, were carried out according to the manufacturer’s manual (Wondfo, Guangzhou, China). Subsequently, two or three drops of blood were spotted on Whatman 3MM filter paper, air dried, and stored in an individually coded sealed plastic bag containing silica desiccant beads. The bags were stored at 4 °C until use. The study was approved by the Ethical Review Committee of the Hubei University of Medicine and Wuhan City Center for Disease Prevention and Control Ethics Committee. Informed consent was obtained and signed by all participants or their guardians before inclusion in the study and before sample collection.

**Molecular procedures**

Genomic DNA (gDNA) from dried blood spot samples was isolated using the TIANamp Blood DNA Kit (Tiangen Biotech Co., Ltd., Beijing, China) following the manufacturer’s recommendations. DNA samples were stored at −20 °C for further genotyping.

To identify polymorphisms in the *Pfdhfr* (Gene ID: PF3D7_0417200) and *Pfdhps* (Gene ID: PF3D7_0810880) genes, purified gDNA templates were amplified by using nested PCR in the Mini MJ Thermal Cycler (Bio-Rad), following protocols described previously with minor changes [19, 20]. Briefly, primary PCR, was performed in a total of 20 μl containing 10 μl of 2 × Phusion PCR Master Mix (40 units/ml Phusion DNA polymerase, 400 μM deoxynucleoside triphosphate [dNTP] mixture, 2 × Phusion high-fidelity [HF] buffer, and 3 mM Mg2+), 1 μl of each primer (10 μM), and 2 μl of gDNA. For the second round, 1.0 μl of primary PCR products were amplified with a 50 μl reaction system. All PCR conditions conducted were as follows: predenaturation at 95 °C for 3 min, followed by 30 cycles of denaturing for 30 s at 95 °C, annealing for 30 s at 55 °C and extension at 72 °C.
for 30 s, plus a final extension at 72 °C for 5 min. The PCR product was electrophoresed on a 1.0% agarose gel stained with GelRed® Safe DNA Gel Stain (Boitium, USA) and visualized with a UV transilluminator. Sequencing was outsourced to Genewiz, Soochow, China, whereby for the PfΔfr gene, the nested PCR products were purified and sequencing in reverse directions, while for the PfΔps gene, the nested PCR products were purified and sequenced by Bidirectional DNA sequencing. Polymorphisms were analysed by creating consensus nucleotide sequences with the reference sequences in PlasmoDB using DNASTar (DNASTAR Inc., Madison, WI, USA).

Statistical analysis
The frequencies of single-nucleotide polymorphisms (SNPs) and haplotypes were calculated as the percentage of the number of successful sequencing samples. Mixed infections containing wild-type and mutation were excluded from further analysis. The comparison and trend estimation of haplotypes were assessed by unpaired T-test and linear regression analysis respectively with GraphPad Prism 5.

Results
Molecular surveillance of PfΔfr and PfΔps mutations
In total, 303 isolates from 2011 to 2019 were included for the analysis of PfΔfr and PfΔps mutations. Table 1 summarizes the different SNPs observed in the samples collected over these years. For PfΔfr, mutations at different loci, including N51I, C59R, S108N, and I164L, were investigated. Of the 300 samples successfully genotyped for the PfΔfr gene, 90.7% (272/300) harboured the mutant allele N51I, while six samples (2.0%) had a mixed type. For the PfΔfr codon at 59, 84.7% (254/300) samples had the mutant allele C59R, and 9 (3%) had mixed genotypes. At codon 108, 94.7% (284/300) harboured a mutation, 3.0% (9/300) were wild type, and 2.3% (7/300) mixed infection were found. Only 1 sample out of 300 (0.3%) derived from Myanmar in 2011 had the highly drug resistant mutation I164L. However, we did not observe any mutation at codon 50 of PfΔfr. For PfΔps mutations at different loci, including S436A, A437G, K540E, A581G, and A613S, were surveyed. Of the 290 (290/303, 95.7%) successful genotyped samples, 27.2% of the isolates harboured S436A, 79.0% harboured A437G, 21.7% harboured K540E, 9.0% harboured A581G and 11.0% harboured A613S. For wild type, 66.0% of the isolates harboured S436A, 13.1% A437G, 70.3% K540E, 85.5% A581G and 89.0% A613S, respectively. For mixed genotypes, 6.9% of the isolates harboured S436A, 7.9% harboured A437G, 5.7% harbour A581G and 0.3% harboured A613S.

Prevalence of the PfΔfr and PfΔps haplotypes
In total, five unique haplotypes at the PfΔfr locus and 11 haplotypes at the PfΔps locus were found. The prevalence of the PfΔfr and PfΔps haplotypes in different years and various geographical regions are illustrated in Fig. 1. The PfΔfr mutations were the most prevalent, with the triple mutation (IRNI) in almost 84.4% (238/282). Compared to the haplotypes of NCSI, ICNI, and NRNI, the IRNI displayed a higher prevalence during 2011–2019 (P<0.0001, P<0.0001, and P<0.0001, respectively) (Fig. 1a). As the predominant haplotype, the IRNI was found in all geographical areas in Africa and SEA (Fig. 1b). For ICNI (wild type), the frequency has increased from none in 2011 to 2012 to 9.1% (3/33) in 2018, and then reduced to 2.5% (1/40) in 2019. The relative frequencies of the ICNI mutations decreased from 16.67% (1/6) in 2011 to 0 in 2012 and increased to 14.3% (6/42) in 2013; finally stabilized at 15.0% (6/40) in 2019. For NRNI, there was only a marginal difference over these years (F=0.6316, P=0.4529). The allele with quadruple mutations (IRNL), which conferred a high level of resistance to antifolates, was only found at a low frequency (0.3%, 1/300) in 2011. For PfΔps, the predominant haplotype was single-mutant SGKAA (37.8%, 90/238). It was increased from 14.3% (1/7) in 2011 to 30.0% (9/30) in 2019 (Fig. 1c). Although a decreasing trend was observed in the prevalence of the quadruple-mutant AGKGS from 18.5% in 2012 to 9.8% in 2016 and finally to 0% in 2019, these differences were not statistically significant (F=0.0063, P=0.9391). Similarly, the prevalence of the PfΔps wild type SAKAA genotype has decreased from 42.9% in 2011 to 3.3% in 2019, but it was not statistically significant (F=4.456, P=0.0727). The PfΔps double-mutant AGKAA genotype decreased from 14.3% in 2011 to 7.3% in 2016.

Table 1 Observed the overall frequency of mutations in PfΔfr and PfΔps

| Gene | Mutations | Wild type (%) | Mutation (%) | Mixed type (%) | Total |
|------|-----------|---------------|-------------|---------------|-------|
| PfΔfr | N51I      | 22 (7.3)      | 272 (90.7)  | 6 (2.0)       | 300   |
|       | C59R      | 37 (12.3)     | 254 (84.7)  | 9 (3.0)       | 300   |
|       | S108N     | 9 (3.0)       | 284 (94.7)  | 7 (2.3)       | 300   |
|       | I164L     | 299 (99.7)    | 1 (0.3)     | 0 (0.0)       | 300   |
| PfΔps | S436A     | 191 (65.9)    | 79 (27.2)   | 20 (6.9)      | 290   |
|       | A437G     | 38 (13.1)     | 229 (79.0)  | 23 (7.9)      | 290   |
|       | K540E     | 204 (70.3)    | 63 (21.7)   | 23 (7.9)      | 290   |
|       | A581G     | 248 (85.5)    | 26 (9.0)    | 16 (5.5)      | 290   |
|       | A613S     | 258 (89.0)    | 31 (11.0)   | 1 (0.3)       | 290   |

Mutations are shown in underline and bold.
and finally increased to 16.7% in 2019 ($F = 0.6879$, $P = 0.4342$). A concomitant increase in the prevalence of the Pfdhps double-mutant SGEAA genotype was observed, increasing in prevalence from 3.7% in 2012 to 33.3% in 2019, which was statistically significant ($F = 9.034$, $P = 0.0198$) (Fig. 1c). As the predominant haplotype, the SGKAA was mostly found in WA, CA, and SA with a prevalence of 93.4, 47.5, and 42.9%, respectively (Fig. 1d). SGEAA, was mostly distributed in SA (36.7%), EA (76.2%), and CA (17.0%) (Fig. 1d).

**Prevalence of Pfdhfr and Pfdhps combination haplotypes**

A total of 230 samples were subjected to combined haplotypes analysis. The 28 haplotypes were verified by
combining both genes. The most common haplotype was IRNI-SGKAA with a 30.0% (69/230) frequency, followed by IRNI-SGEAA (20.4%, 47/230), IRNI-AGKAA (9.8%, 22/230), and IRNI-AGKGS (7.8%, 18/230). Moreover, the frequency distribution of the different Pf\text{dhfr}-Pf\text{dhps} haplotypes was compared among the analysed samples collected at different times. The results showed that the most prevalent haplotype observed during the study period was IRNI-SGKAA, which also remained the most frequent one in WA (32.7%), SA (23.4%), and CA (44.4%) (Fig. 1e). For IRNI-SGEAA, an increasing trend was detected during 2011–2016, and 2017–2019, respectively (Fig. 1e). For regional distribution, IRNI-SGKAA was mainly distributed in WA (32.7%), CA (44.4%), and SA (23.4%) (Fig. 1f). Similarly, IRNI-SGEAA was mainly found in EA (71.4%) and SA (31.9%), followed by CA (16.7%) and WA (7.1%) (Fig. 1f). An additional 20 minor haplotypes with a prevalence of less than 2% constituted only 9.1% (21/227) of the overall haplotypes (Additional file 1: Table S1 and Additional file 2: Table S2).

**Discussion**

Globally, strategies for malaria control have substantially reduced the disease burden in the last few decades. Soon afterward, several nations in Asia (particularly China), Africa, and Latin America began advancing towards malaria elimination [21–23]. However, imported malaria from Africa and SEA has affected and delayed the progress of malaria elimination in China. Furthermore, drug-resistant P. falciparum parasites will become a significant challenge influencing the process of malaria control, elimination, and eradication. The SNPs in the Pf\text{dhfr} and Pf\text{dhps} genes are linked to the failure of SP treatment against uncomplicated P. falciparum malaria and have been documented in Africa and SEA for several decades [10, 11]. However, there are no such data to support drug policies in nonendemic areas with imported malaria in China particularly Wuhan [24]. To determine whether parasites carrying these polymorphisms exist in Wuhan, molecular surveillance were conducted targeting Pf\text{dhfr} and Pf\text{dhps} gene polymorphisms in imported clinical isolates.

For Pf\text{dhfr}, the critical event in the development of pyrimethamine resistance is a mutation in codon 108 that changes serine (S) to asparagine (N), resulting in partial pyrimethamine resistance. Further mutations at N51I and/or C59R increase the level of pyrimethamine resistance [25]. Under continuous pyrimethamine selective drug pressure, the SNP adaptations in our data have also followed this rule. The current survey demonstrated an extremely high prevalence (>84%) of three mutations (N51I, C59R, and S108N) in P. falciparum clinical isolates imported from Africa and SEA. In Africa, Pf\text{dhfr} nonsynonymous polymorphisms have also been reported at high frequencies in isolates from Uganda [26], Angola [27], the Democratic Republic of the Congo [12], Nigeria [28], and Sierra Leone [29]. Parasitic infections carrying the Pf\text{dhfr} triple mutant (IRNI) are significantly more likely to be resistant to SP treatment than infections with fewer Pf\text{dhfr} mutations [30]. Most of the isolates in our dataset had the triple mutant allele IRNI (84.4%, 238/282), indicating that pyrimethamine resistance remains at a relatively high level in Africa. However, no mutations in codons 50 and 164 of Pf\text{dhfr} were detected in samples collected on the African continent. An additional mutation, I164L, confers an elevated level of pyrimethamine resistance that could render SP invalid [27]. Although the Pf\text{dhfr} I164L mutation was first reported from Kenya [31] and then was found in Madagascar [32] and the Central African Republic [33], it was not detected in Africa in the present study. Furthermore, only one sample (0.3%, 1/300) with the I164L mutation was found in 2011 from SEA (Myanmar).

For Pf\text{dhps}, as the key mutation associated with sulfadoxine resistance, a single amino acid residue changes from alanine (A) to glycine (G) at codon 437 of Pf\text{dhps} [34]. The A437G selection by SP has been previously described during IPTi [35]. As the most frequent mutation of Pf\text{dhps}, our findings illustrate the high prevalence of A437G at 79.0% (229/290), which has also been reported to be nearly at a saturation level in most African countries [27]. Furthermore, a higher proportion of A437G has been detected at 75.6% in Gabon [36], 87.9% in Kenya [37], 97.6% (1416/1451) in Congo [12], and 96.4% (27/28) in Nigeria [28]. Thus, it needs to be kept in mind that a high prevalence of SP-resistant parasites is present in these regions. More attention should be given to SP drug resistance surveillance, both in these countries and in nonendemic areas, particularly Wuhan, which is influenced by imported malaria from endemic areas. Compared to the high prevalence of Pf\text{dhfr} mutations, a low prevalence (<30%) of four mutant alleles (S436G, A581S/T, H591A, and K540E) in Pf\text{dhps} was detected. It has been reported that Pf\text{dhps} K540E has a low prevalence in Central and West Africa [9, 14, 28, 33]. In contrast, the K540E mutation is common in East Africa [38, 39], similar to our findings. The Pf\text{dhps} A581G and A613S/T mutations have been detected at a low prevalence in WA and EA, but a rapid emergence of these mutations has been described in Kenya and Uganda [25, 33, 40].
from Nigeria and Cameroon, these mutations have not been found in CA [41]. In Cameroon, there is an increasing trend in the prevalence of the Pfdhps A581G and A613S mutations [33]. In the current study, the prevalence of A581G and A613S were generally consistent with these observations in Africa.

Parasites carrying all five mutations, the Pfdhfr triple mutant (N51I+C59R+S108N) and the Pfdhps double mutant (A437G and K540E), commonly called the quintuple mutation (IRNI-SGEAA), have been strongly associated with SP treatment failure in sub-Saharan Africa [42–45]. Alarming, the present study found 18.54% of tested isolates harboured fully resistant (IRNI-SGEAA), which is common in EA [34, 46]. Additional mutations in Pfdhfr 1164L and Pfdhps A581G have been associated with a high level of SP resistance and failure [47]. However, a quintuple mutant named “super-resistant genotypes” is linked with a more than triple enhancement of therapeutic failure [47]. The IRNI-SGEAA forming the sextuple haplotype has been connected with an optimal resistance effect, referred to as the “super-resistant genotype” [37]. Three isolates of such genotype are found in our data, which is of concern. In addition, it is noteworthy that the other combined haplotypes, including the quintuple mutant (IRNI-AGKAA, IRNI-SGKAS, ICNI-SGEAA), the sextuple mutant (IRNI-AGKAS, NRNI-AGKGS, IRNI-AGEAA), and the septuple mutant (IRNI-AGKGS, IRNL-SGEAA), were also detected in the current data. Previous studies revealed that IRNI-SGEAA, IRNI-AGEAA has been highly associated with a lack of IPTp-SP efficacy [48]. It was illustrated that such genotypes were widely distributed in Tanzania, in line with our study, where one isolate harboured the sextuple haplotype (IRNI-SGEAA), which happened to come from Tanzania [48]. Interestingly, the septuple mutant haplotype (IRNI-AGKGS) accounts for a certain proportion of our findings, which is similar to a previous study reported in Nigeria [3]. This demonstrates that SP resistance remains at a moderate level in Africa. Although SP is recommended as an effective anti-malarial drug used for the vulnerable population [35], more attention needs to be paid to these mutations profiles.

Conclusions
In conclusion, the present study reports the persistence of P. falciparum parasites with Pfdhfr and Pfdhps mutations associated with SP resistance in migrant workers returning from Africa and SEA to Wuhan, central China. These findings provide fundamental prevalence data that enable a policy-making organization to directly determine the best measures and strategies for malaria control and elimination.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12936-020-03509-w.

Additional file 1: Table S1. Haplotypes distribution of Pfdhfr and Pfdhps in a different country during 2011-2019.

Additional file 2: Table S2. The combined haplotypes distribution of Pfdhfr and Pfdhps in different years and areas.

Abbreviations
A: Alanine; G: Glycine; N: Asparagine; S: Serine; ACTs: Artemisinin-based combination therapies; CQ: Chloroquine; gDNA: Genomic DNA; Pfdhfr: P. falciparum Dihydrofolate reductase; IPTi: Intermittent preventive treatment in infants; IPTp: Intermittent preventive treatment pregnant women; RDTs: Rapid diagnostic tests; Pf-HRP2: P. falciparum Specific Histidine-rich protein 2; pLDH: Plasmodium lactate dehydrogenase; SMC: Seasonal Malaria Chemoprevention; SEA: Southeast Asia; SP: Sulfadoxine-pyrimethamine; SNPs: Single-nucleotide polymorphisms.

Acknowledgements
The authors would like to thank the Department of Schistosomiasis and Endemic Diseases, Wuhan Center for Disease Prevention and Control, and all participants who have contributed their blood samples.

Authors’ contributions
JL conceived and designed the experiments. KW coordinated the field collections of patient isolates. KW carried out a microscopic examination and RDTs. TTJ, WJC, and YY performed the experiments. JL, TTJ, WJC, and HBT analysed the data. JL and TTJ wrote the paper. All the authors read and approved the final manuscript.

Funding
This study was supported by the Foundation for Innovative Research Team of Hubei University of Medicine (Grant Number FDFR201603) and the National Natural Science Foundation of China (Grant Number 81802046).

Availability of data and materials
The datasets analysed in this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The current study was approved by the ethics committees of the Hubei University of Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China. Department of Schistosomiasis and Endemic Diseases, Hubei University of Medicine, Shiyan 442000, China.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Human Parasitology, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. 2 Department of Infectious Diseases, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China. 3 Department of Schistosomiasis and Endemic Diseases, Wuhan City Center for Disease Prevention and Control, Wuhan 430015, China.

Received: 28 May 2020 Accepted: 19 November 2020

Published online: 25 November 2020

References
1. World Health Organization. World malaria report 2019. Geneva: World Health Organization; 2019.
39. Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhayamikaka E, Asua V, et al. Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda. J Infect Dis. 2017;215:631–5.

40. Naidoo I, Roper C. Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology. 2011;138:1469–79.

41. Sutherland CJ, Fifer H, Pearce RJ, Bin Reza F, Nicholas M, Haustein T, et al. Novel pfHdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom. Antimicrob Agents Chemother. 2009;53:3405–10.

42. Greenhouse B, Slater M, Njama-Meya D, Nzarubara B, Maitieki-Sebuguzi C, Clark TD, et al. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis. 2009;199:758–65.

43. Andrews KG, Lynch M, Eckert E, Gutman J. Missed opportunities to deliver intermittent preventive treatment for malaria to pregnant women 2003–2013: a systematic analysis of 58 household surveys in sub-Saharan Africa. Malar J. 2015;14:521.

44. Shah M, Omosun Y, Lal A, Odero C, Gatei W, Otieno K, et al. Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya. Malar J. 2015;14:75.

45. Ravenhall M, Benavente ED, Mipando M, Jensen AT, Sutherland CJ, Roper C, et al. The impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi. Malar J. 2016;15:575.

46. Matondo SI, Temba GS, Kavishe AA, Kauki JS, Kalinga A, van Zwetselaar M, et al. High levels of sulfadoxine-pyrimethamine resistance PfHdhf-PfHdhp quintuple mutations: a cross sectional survey of six regions in Tanzania. Malar J. 2014;13:152.

47. Rouhani M, Zakeri S, Pirahmadi S, Raeesi A, Djadid ND. High prevalence of PfHdhf-pfhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran. Infect Genet Evol. 2015;31:183–9.

48. Baraka V, Ishengoma DS, Fransis F, Minja DT, Madebe RA, Ngatunga D, et al. High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Malar J. 2015;14:439.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.